Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study

References

• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):1–10. doi: 10.1146/annurev-pathol-042020-042741.
   PubMedGoogle Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. doi: 10.1016/S0140-6736(21)01206-X.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020;97(1):62–74. doi: 10.1016/j.kint.2019.07.022.
   PubMed Web of Science ®Google Scholar
• Pico de Coaña Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015;21(8):482–491. doi: 10.1016/j.molmed.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Sprangers B, Leaf DE, Porta C, et al. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022;18(12):794–805. doi: 10.1038/s41581-022-00630-8.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi: 10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Franzin R, Netti GS, Spadaccino F, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do We stand? Front Immunol. 2020;11:574271. doi: 10.3389/fimmu.2020.574271.
   PubMed Web of Science ®Google Scholar
• Xie W, Xiao S, Li X, et al. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence. Eur J Intern Med. 2023;115:88–95. doi: 10.1016/j.ejim.2023.05.034.
   PubMed Web of Science ®Google Scholar
• Herrmann SM, Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep. 2020;5(8):1139–1148. doi: 10.1016/j.ekir.2020.04.018.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29(8):2039–2052. doi: 10.1681/ASN.2018050488.
   PubMed Web of Science ®Google Scholar
• Espi M, Teuma C, Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: immuNoTox study. Eur J Cancer. 2021;147:29–39. doi: 10.1016/j.ejca.2021.01.005.
   PubMed Web of Science ®Google Scholar
• Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020;8(1):e000467. doi: 10.1136/jitc-2019-000467.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor–associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–446. doi: 10.1681/ASN.2019070676.
   PubMed Web of Science ®Google Scholar
• Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(10):e003467. doi: 10.1136/jitc-2021-003467.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Zhao S, Strohbehn IA, et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep. 2020;5(10):1700–1705. doi: 10.1016/j.ekir.2020.07.011.
   PubMed Web of Science ®Google Scholar
• Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol. 2018;13(12):1851–1858. doi: 10.2215/CJN.01390118.
   PubMed Web of Science ®Google Scholar
• González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–946. doi: 10.1038/sj.ki.5002776.
   PubMed Web of Science ®Google Scholar
• Marco T, et al. The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Ther Adv Med Oncol. 2019;11:1758835919875549.
   Web of Science ®Google Scholar
• Section 2: AKI definition. Kidney Int Suppl (2011). 2012;2(1):19–36.
   PubMedGoogle Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. doi: 10.1159/000339789.
   PubMedGoogle Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257. doi: 10.1038/nrneph.2017.2.
   PubMed Web of Science ®Google Scholar
• Liu K, Qin Z, Xu X, et al. Comparative risk of renal adverse events in patients receiving immune checkpoint inhibitors: a Bayesian network meta-analysis. Front Oncol. 2021;11:662731. doi: 10.3389/fonc.2021.662731.
   PubMedGoogle Scholar
• Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–1700. doi: 10.2215/CJN.00990119.
   PubMed Web of Science ®Google Scholar
• Stepkowski S, et al. Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. Plos One. 2021;16(6):e0252978.
   Web of Science ®Google Scholar
• Gupta S, Cortazar FB, Riella LV, et al. Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360. 2020;1(2):130–140. doi: 10.34067/KID.0000852019.
   PubMedGoogle Scholar
• Rao Ullur A, Côté G, Pelletier K, et al. Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. Clin Kidney J. 2023;16(6):939–951. doi: 10.1093/ckj/sfad014.
   PubMed Web of Science ®Google Scholar
• Qin Z, Liu K, Xu X, et al. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors. Future Oncol. 2022;18(16):1951–1962. doi: 10.2217/fon-2021-1004.
   PubMed Web of Science ®Google Scholar
• Yan H, Tang M, Zhu W, et al. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors. Clin Exp Nephrol. 2023;27(7):603–612. doi: 10.1007/s10157-023-02344-y.
   PubMed Web of Science ®Google Scholar
• Singh P, Rifkin DE, Blantz RC. Chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(9):1690–1695. doi: 10.2215/CJN.00830110.
   PubMedGoogle Scholar
• Tian R, Liang J, Li R, et al. Acute kidney injury induced by immune checkpoint inhibitors. Kidney Dis. 2022;8(3):190–201. doi: 10.1159/000520798.
   Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647. doi: 10.1016/j.kint.2016.04.008.
   PubMed Web of Science ®Google Scholar
• De Giglio A, Grandinetti V, Aprile M, et al. Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): a single-center experience. Lung Cancer. 2022;174:91–96. doi: 10.1016/j.lungcan.2022.10.007.
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160–169. doi: 10.1159/000455014.
   PubMed Web of Science ®Google Scholar
• Longhitano E, Muscolino P, Lo Re C, et al. Immune checkpoint inhibitors and the kidney: a focus on diagnosis and management for personalised medicine. Cancers. 2023;15(6):1891. doi: 10.3390/cancers15061891.
   PubMed Web of Science ®Google Scholar
• Teixeira FJ, Santos HO, Howell SL, et al. Whey protein in cancer therapy: a narrative review. Pharmacol Res. 2019;144:245–256. doi: 10.1016/j.phrs.2019.04.019.
   PubMed Web of Science ®Google Scholar
• Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med. 2010;36(10):1657–1665. doi: 10.1007/s00134-010-1928-z.
   PubMed Web of Science ®Google Scholar
• Vaddepally R, Doddamani R, Sodavarapu S, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)—their incidence, management, multiorgan irAEs, and rechallenge. Biomedicines. 2022;10(4):790. doi: 10.3390/biomedicines10040790.
   PubMed Web of Science ®Google Scholar
• Wang Q, Moledina DG, Sise ME. Immune checkpoint inhibitors and kidney disease. Curr Opin Nephrol Hypertens. 2022;31(5):449–455. doi: 10.1097/MNH.0000000000000805.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Herrmann SM, Rashidi A. Immune checkpoint inhibitor–associated AKI: debates in diagnosis, management, and rechallenge. Semin Nephrol. 2022;42(6):151346. doi: 10.1016/j.semnephrol.2023.151346.
   PubMed Web of Science ®Google Scholar
• Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7(1):2. doi: 10.1186/s40425-018-0478-8.
   PubMedGoogle Scholar